Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, April 12, 2022
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
[ Tue, Apr 12th 2022
] - WOPRAI
Matthew Harrison Maintained (BMRN) at Hold with Increased Target to $96 on, Apr 12th, 2022
Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Hold with Increased Target from $90 to $96 on, Apr 12th, 2022.
Matthew has made no other calls on BMRN in the last 4 months.
There is 1 other peer that has a rating on BMRN. Out of the 1 peers that are also analyzing BMRN, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $125 on, Thursday, February 24th, 2022
